Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Paraganglioma 1Neuroendocrine Tumors 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

Specimen Handling 3Nivolumab 3Ipilimumab 3Biopsy 3prednylidene 2pembrolizumab 2deltacortene 2Prednisone 2Magnetic Resonance Spectroscopy 2CTLA-4 Antigen 2talimogene laherparepvec 1oblimersen 1cixutumumab 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tacrolimus 1Sirolimus 1Salts 1Radiosurgery 1Octreotide 1Imatinib Mesylate 1Everolimus 1Complementary Therapies 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Merkel Cell × Acetates × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡